Catalyst Pharmaceuticals, Inc.
US ˙ NASDAQCM ˙ US14888U1016 ˙ Medical Devices
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionGTTMX - Quantitative U.S. Total Market Equity Portfolio
Latest Disclosed Ownership25,662 shares
Latest Disclosed Value $ 721,872
GTTMX - Quantitative U.S. Total Market Equity Portfolio reports 20.99% decrease in ownership of CPRX / Catalyst Pharmaceuticals, Inc.

On June 4, 2026 - GTTMX - Quantitative U.S. Total Market Equity Portfolio filed a NPORT-P form disclosing ownership of 25,662 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $721,872 USD as of April 30, 2026. The entity filed a previous NPORT-P on March 12, 2026 disclosing 32,480 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of -20.99% during the quarter. The current value of the position is $808,096 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-06-04 2026-04-30 NP Catalyst Pharmaceuticals EC US14888U1016 25,662 -6,818 -20.99 722 -8.62 2.9395
2026-03-12 2026-01-31 NP Catalyst Pharmaceuticals EC US14888U1016 32,480 0 0.00 789 14.35 2.5802
2025-12-08 2025-10-31 NP Catalyst Pharmaceuticals EC US14888U1016 32,480 0 0.00 691 -0.29 2.2051
2025-09-17 2025-07-31 NP Catalyst Pharmaceuticals EC US14888U1016 32,480 0 0.00 693 -12.18 2.2515
2025-06-05 2025-04-30 NP Catalyst Pharmaceuticals EC US14888U1016 32,480 -6,180 -15.99 789 -9.63 2.7388
2025-03-07 2025-01-31 NP Catalyst Pharmaceuticals EC US14888U1016 38,660 0 0.00 872 3.56 2.6591
2024-12-05 2024-10-31 NP Catalyst Pharmaceuticals EC US14888U1016 38,660 0 0.00 843 26.43 2.3542
2024-09-16 2024-07-31 NP Catalyst Pharmaceuticals EC US14888U1016 38,660 0 0.00 666 14.63 1.7946
2024-06-07 2024-04-30 NP Catalyst Pharmaceuticals EC US14888U1016 38,660 0 0.00 582 4.50 1.6246
2024-03-15 2024-01-31 NP Catalyst Pharmaceuticals EC US14888U1016 38,660 0 0.00 557 16.08 1.5137
2023-12-05 2023-10-31 NP Catalyst Pharmaceuticals EC US14888U1016 38,660 38,660 480 1.3376
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.